Zartash Gul
Overview
Explore the profile of Zartash Gul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams M, Atienza S, Franzen E, Rathod H, Mejaki B, Graff J, et al.
Open Forum Infect Dis
. 2024 Nov;
11(11):ofae622.
PMID: 39498172
Background: Evaluations of oral vancomycin prophylaxis (OVP) against have been reported in stem cell transplant populations with short follow-up periods. The longest known duration of standardized follow-up post-OVP is 90...
2.
Yu T, Gul Z, Hunt A, Williams M, Maley A
Cureus
. 2024 Sep;
16(8):e66974.
PMID: 39280467
Program death 1 (PD-1) inhibitors such as nivolumab are immune checkpoint inhibitors that have revolutionized the treatment of metastatic melanoma. Despite its success in treating melanoma, immune activation can lead...
3.
Williams M, Atienza S, Aranda R, Flint K, Sana S, Medlin S, et al.
J Patient Cent Res Rev
. 2024 Jul;
11(2):81-87.
PMID: 39044850
Purpose: The impact of central nervous system (CNS) prophylaxis in diffuse large B-cell lymphoma (DLBCL) is contentious. The CNS International Prognostic Index (IPI) calculator offers prognostic guidance in identifying those...
4.
Williams M, Gul Z, Graff J, Mejaki B, Sana S, Medlin S
J Oncol Pharm Pract
. 2024 May;
:10781552241252606.
PMID: 38706250
Initial continuous intravenous (CIV) tacrolimus (0.03 mg/kg/day based on ideal body weight [IBW]) has been favored for graft versus host disease (GVHD) prevention in allogeneic stem cell transplant patients due...
5.
Al-Kadhimi Z, Pirruccello S, Gul Z, Maness-Harris L, Bhatt V, Gundabolu K, et al.
Bone Marrow Transplant
. 2022 Aug;
57(10):1629-1631.
PMID: 35953707
No abstract available.
6.
Barreyro L, Sampson A, Ishikawa C, Hueneman K, Choi K, Pujato M, et al.
Sci Transl Med
. 2022 Mar;
14(635):eabb7695.
PMID: 35263148
Dysregulation of innate immune signaling pathways is implicated in various hematologic malignancies. However, these pathways have not been systematically examined in acute myeloid leukemia (AML). We report that AML hematopoietic...
7.
Ohanian M, Cancelas J, Davenport R, Pullarkat V, Hervig T, Broome C, et al.
Am J Hematol
. 2021 Nov;
97(3):256-266.
PMID: 34748664
Thrombosomes are trehalose-stabilized, freeze-dried group O platelets with a 3-year shelf life. They can be stockpiled, rapidly reconstituted, and infused regardless of the recipient's blood type. Thrombosomes thus represent a...
8.
Ahmed G, Khan R, Kamireddy C, Qadir H, Khan I, Gul Z
Am J Ther
. 2020 Sep;
27(5):e543-e547.
PMID: 32902938
No abstract available.
9.
Zhou Z, Nath R, cerny J, Wang H, Zhang M, Abdel-Azim H, et al.
Blood Adv
. 2020 Jul;
4(13):3180-3190.
PMID: 32663298
There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult...
10.
Sheikh M, Toledano M, Ahmed S, Gul Z, Hashmi S
Hematol Oncol Stem Cell Ther
. 2020 Jun;
14(2):87-94.
PMID: 32516577
Objective/background: Neurological complications occur at a high frequency after hematopoietic cell transplantation (HCT). However, an absence is noted in the published literature as regards the quantification of the exact burden...